VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the 4th Annual Immuno-Oncology Summit on Wednesday, August 31, 2016 at 11:15 AM ET. The event is being held at the Marriott Long Wharf Hotel in Boston, MA.
During the presentation, eVLP Delivery of Novel Foreign Antigens Elicits Polyvalent Anti-Tumor Immunity, Adam Buckley, VBI’s Vice President of Business Development, will summarize recent progress in the company’s glioblastoma multiforme (“GBM”) and medulloblastoma (“MB”) immunotherapy programs, including new data that demonstrates VBI-1901’s ability to stimulate dendritic cell responses. Download Presentation PDFVBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. VBI has applied its eVLP Platform in the development of VBI-1901, a multivalent therapeutic vaccine candidate designed to direct an immune response against cytomegalovirus (“CMV”) viral antigens that are frequently expressed in certain cancers, including GBM1, MB2, and breast3. In preclinical studies, VBI-1901 stimulated immune responses critical to efficacious anti-tumor immunity, including CD4+ and CD8+ T cell responses in GBM patient samples.
New preclinical data demonstrates VBI-1901’s ability to recruit and activate dendritic cells, as evidenced by induction of proinflammatory IL-8 cytokine and CCL3 chemokine responses in an ex vivo model. Dendritic cells are critical to antigen presentation and the initiation of an adaptive immune response.
“VBI-1901 has the potential to be an off-the-shelf immunotherapy that activates both T cells and dendritic cells,” said Mr. Buckley. “Leveraging tumor associated viral antigens, in this case CMV, allows VBI-1901 to harness the immune system’s vigorous antiviral response to directly target CMV-infected tumors.”
- Event: 4th Annual Immuno-Oncology Summit
- Date: Wednesday, August 31, 2016
- Time: 11:15 AM ET
- Location: Marriott Long Wharf Hotel in Boston, MA
- Event Website: http://www.immuno-